@

> english version Imprint

 

Impressum

 

Sciomics GmbH
Karl-Landsteiner-Str. 6
69151 Neckargemünd
Telefon: +49 6221 4294830
Telefax: +49 6221 4294834
E-Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Internet: http://www.sciomics.de
Sciomics GmbH wird vertreten durch: Geschäftsführer Dr. Christoph Schröder

 

Registergericht: Amtsgericht Mannheim
Handelsregister
Registernummer: HRB716969

Umsatzsteuer-Identifikationsnummer gemäß § 27a Umsatzsteuergesetz: DE289272460

 

Urheberrecht

Alle Inhalte der Internetpräsenz der Sciomics GmbH sind urheberrechtlich geschützt. Dies gilt für Texte wie auch Fotos, Grafiken sowie PDF-Dokumente.
Jede Vervielfältigung oder Verbreitung dieses Internetangebotes oder auch von Inhalten, Auszügen, Dateien oder anderen Teilen davon, zum Beispiel zum Nachdruck, zur Kopie in andere Internetseiten oder zur Weitergabe in elektronischer Form, bedarf der schriftlichen Genehmigung der Sciomics GmbH.

 

Haftung

Trotz sorgfältiger inhaltlicher Kontrolle übernehmen wir keine Haftung für die Inhalte externer Links. Für den Inhalt der verlinkten Seiten sind ausschließlich deren Betreiber verantwortlich.

 

 

 

Imprint

 

Sciomics GmbH
Karl-Landsteiner-Str. 6
69151 Neckargemünd
Phone: +49 6221 4294830
Fax: +49 6221 4294834
E-Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Internet: http://www.sciomics.de
Sciomics GmbH is represented by: Geschäftsführer Dr. Christoph Schröder

 

Register jurisdiction: Amtsgericht Mannheim
Commercial Register
Registration number: HRB716969

Umsatzsteuer-Identifikationsnummer (VAT identification number) according to §27a of the Umsatzsteuergesetz (UStG, Sales Tax Law): DE289272460

 

Copyright

The layout, texts, text fragments and graphics used and any other contents on the homepage protected by copyright law. All rights reserved.

 

Liability

Links have been proved during setup. Since information on the WWW is subject of current change Sciomics accepts no responsibility with regard to such problems, or the consequences thereof, incurred as a result of using this site or any linked external sites.
This disclaimer is not intended to contravene any requirements laid down in applicable national law nor to exclude liability for matters which may not be excluded under that law.


 

 

 

 

COVID-19 related activities and services

covid 19 portfolio web

News

New Article | Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia

| September 2023 | New Article: Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia. Sciomics supported this study by scioCyto serum analysis in a mouse cancer model.

Taylor, J., Uhl, L., Moll, I. et al. Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia. Nat Cancer 4, 1544–1560 (2023). 
New Article | Rapid Diagnostic Platform for Personalized Vitamin B6 Detection in Erythrocytes

| July 2023 | New Article: Fiedler et al. developed a novel methodology for vitamin B6 diagnostics. We supported the project by the production of custom antibody microarray targeting signature human PLP-DE and testing respective samples.

Fiedler et al. Rapid Diagnostic Platform for Personalized Vitamin B6 Detection in Erythrocytes via PLP Cofactor Mimics (2023) ACS Chem Biol.
New Article | Microbiota Influences Chemotherapy in Pancreatic Cancer

| February 2023 | New Article: In the study Tintelnot et al. identified a microbiota-derived metabolite that has clinical implications in the treatment of pancreatic cancer. Sciomics supported the authors by a protein profiling study of tumours derived from a mouse model upon treatment with 3-IAA and Firinox.

Tintelnot et al. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Nature 615, 168-174 (2023)
New Article | Predicting a severe Covid-19 disease

| April 2023 | New Article: In a protein biomarker development project initiated by Sciomics, we have identified protein biomarker panels predicting development of a severe Covid.19  disease.

Hufnagel K., Fathi A. et al. Discovery and systematic assessment of early biomarkers that predict progression to severe COVID-19 disease. Communications Medicine 3,51 (2023)
New Sciomics Proteomics Research Blog has Launched!

Sciomics Protomics Research Blog

 

At Sciomics, we are dedicated to advancing healthcare through proteomics research. We are collaborating with research groups and big pharma, alongside our in-house biomarker research initiatives. To make this research more accessible to you, we are launching the new Sciomics science blog!

The first study we will feature was published this year in a journal in the Nature publishing group. It's a topic that affects us all. Any guesses? Stay tuned!

 

 

Testimonials

Dr. Matthew Wright

Chief Scientific Officer, Kinarus Therapeutics AG, Basel, Switzerland

"We are a small biotech company without our own wet labs. Sciomics recommended a UK CRO that performed cell culture experiments for our studies. Sciomics seamlessly coordinated the transfer of the biologic materials to their facility and performed the scioCD panel to characterize cell surface markers and cytokines in cell lines treated with our small molecule drug candidates. The Sciomics data were instrumental in supporting our IP protection strategy. Their advice was very helpful and they worked with us to extract the most out of the data. We are very satisfied and highly recommend the Sciomics platform and the team."

Product: scioCD

Kyriaki Barmpa

PhD Candidate, Developmental and Cellular Biology, Luxembourg Centre for Systems Biomedicine, University of Luxembourg

"By collaborating with Sciomics, we conducted a detailed analysis of the proteome of striatum organoids, uncovering significant differences that further assisted our research. Their communication was highly efficient, and the results were delivered promptly."

Product: scioPhospho

BACK_TO_TOP